Quest Diagnostics (DGX)
NYSE Market Closed
Quest Diagnostics Inc. is one of the largest independent diagnostic testing companies in the United States, serving patients, physicians, hospitals, employers, insurers, and public health organisations. The company’s core business is clinical laboratory testing, where it analyses specimens such as blood, urine, tissue, and other samples to help detect, monitor, and manage disease. Its scale gives it a broad national presence, with thousands of patient access points and relationships across physician offices, health systems, and other care settings.
The company’s testing menu spans routine blood work, anatomic pathology, molecular and genetic testing, women’s health, infectious disease, cardiometabolic testing, oncology, and drug monitoring. Quest also provides more specialised esoteric tests that may require advanced technology or expert interpretation. This breadth makes the company a key part of the healthcare system, as laboratory results influence a large share of medical decisions while often representing a relatively small portion of overall care costs.
Beyond its main diagnostics operations, Quest offers services that support clinical trials, employer health programmes, risk assessment, and healthcare information management. It has also built digital tools that allow patients and clinicians to access results, schedule appointments, and manage testing more efficiently. The business benefits from recurring demand for medical testing, demographic trends such as an ageing population, and the increasing use of diagnostics in personalised medicine. At the same time, it operates in a regulated and competitive market where reimbursement rates, payer contracts, hospital partnerships, and testing innovation are important drivers of performance.
Last updated
- Market Cap
- 21.38B
- P/E
- 20.94
- P/FCF
- 16.13
- P/S
- 1.9
- Enterprise Value
- 26.65B
- Sector
- Health Care
- Industry
- Medical Laboratories
- Address
- 500 PLAZA DRIVE, SECAUCUS, NJ, 07094
Global HPV Testing and Pap Test Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight
Drug Screening Market Trends 2026–2031: Chromatography and Mass Spectrometry Held a 44.77% Share in 2025 Amid Growing Demand for Advanced Testing, Reports Mordor Intelligence
Genomics Services Market Projected to Surpass USD 25.18 Billion by 2035; Increasing Genetic Disorders’ Prevalence is Driving Market Growth Globally – SNS Insider
S&P 500 Earnings Halfway Mark: Sector Winners, Losers, and What Comes Next
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - Privacy, Digital Access, and Rapid Results Accelerate Adoption
Esoteric Testing Research Report 2026 - Global $41.5+ Bn Market Trends, Opportunities, and Forecasts to 2031
Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options
Non-Invasive Prenatal Testing Market is expected to generate a revenue of USD 9.83 Billion by 2031, Globally, at 17.01% CAGR: Verified Market Research®
$43.36 Bn Autism Spectrum Disorder Diagnostics Global Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029F, 2034F
Fertility Test Market Report 2025-2033, with Profiles of Quest Diagnostics, Mayo Clinic Laboratories, Ovation Fertility, Illume Fertility, Proov, BioMerieux, Labcorp, CCRM Fertility, and Maven Clinic
U.S. Drug Screening Market Size to Envision USD 3.84 Billion by 2034
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight
Drug Screening Market Size Worth USD 10.34 Billion by 2034 | CAGR of 4.84% from 2025 to 2034
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
In vitro diagnostics Market Poised for Significant Growth to Reach value of USD 133.24 Billion from 2025 to 2034
Revenue Cycle Management (RCM) Market Size is Expected to Reach USD 873.74 by 2033, Growing at a CAGR of 11%: Straits Research
Alzheimer's Disease Diagnostics Research Report 2024-2034: Global Market to Reach $27.87 Billion - Focus on Cost-Effective Alzheimer's Diagnostics Gaining Momentum
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 21.38B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 26.65B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 20.94
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.9
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 1.9
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 12.15
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 2.36
- EPS
- 9.22
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 1.88%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 16.13
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 11.56
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 1.33B
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 13.86%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 6.12%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.77
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.18
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.08
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.18
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 911.34K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 193.16
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 2.9B | 2.81B | 2.82B | 2.76B | 2.65B |
| Gross profit | 942M | 910M | 949M | 943M | 863M |
| Operating income | 401M | 369M | 409M | 438M | 348M |
| EBITDA | 548M | 514M | 551M | 581M | 488M |
| Net income | 252M | 245M | 243M | 281M | 220M |
| Basic EPS | 2.27 | 2.21 | 2.18 | 2.51 | 1.97 |
| Diluted EPS | 2.24 | 2.18 | 2.16 | 2.47 | 1.94 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 16.67B | 16.23B | 16.2B | 15.97B | 15.8B |
| Total liabilities | 8.93B | 8.94B | 8.82B | 8.62B | 8.75B |
| Total equity | 7.67B | 7.21B | 7.3B | 7.27B | 6.96B |
| Cash & equivalents | 393M | 420M | 432M | 319M | 188M |
| Current assets | 2.57B | 2.38B | 2.41B | 2.2B | 2.08B |
| Current liabilities | 2.18B | 2.28B | 2.13B | 2.02B | 1.44B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 278M | 465M | 563M | 544M | 314M |
| Investing cash flow | -152M | -191M | -201M | -124M | -115M |
| Financing cash flow | -152M | -287M | -247M | -293M | -561M |
| Change in cash | -27M | -12M | 113M | 131M | -361M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 8-K — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — PFEIFFER GARY M | View Filing | |
| form 4 | Form 4 — MAIN TIMOTHY L | View Filing | |
| form 4 | Form 4 — CARTER ROBERT B | View Filing | |
| form 4 | Form 4 — RING TIMOTHY M | View Filing | |
| form 4 | Form 4 — MORRISON DENISE M | View Filing | |
| form 4 | Form 4 — WENTWORTH TIMOTHY C | View Filing | |
| form 4 | Form 4 — Gregg Vicky B | View Filing | |
| form 4 | Form 4 — Doi Tracey | View Filing | |
| form 4 | Form 4 — Diaz Luis | View Filing | |
| form 4 | Form 4 — Lassiter Wright III | View Filing | |
| edgar index | 8-K — QUEST DIAGNOSTICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — QUEST DIAGNOSTICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 424B2 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 424B2 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | FWP — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 10-Q — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 8-K — QUEST DIAGNOSTICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — DELANEY MARK E | View Filing | |
| form 4 | Form 4 — KUPPUSAMY KARTHIK | View Filing | |
| form 4 | Form 4 — KUPPUSAMY KARTHIK | View Filing | |
| form 4 | Form 4 — KUPPUSAMY KARTHIK | View Filing | |
| form 4 | Form 4 — Lassiter Wright III | View Filing | |
| form 4 | Form 4 — CARTER ROBERT B | View Filing | |
| form 4 | Form 4 — Gregg Vicky B | View Filing | |
| form 4 | Form 4 — Plewman Patrick | View Filing | |
| form 4 | Form 4 — SAMAD SAM | View Filing | |
| edgar index | DEF 14A — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | DEFA14A — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| form 4 | Form 4 — WENTWORTH TIMOTHY C | View Filing | |
| edgar index | SCHEDULE 13G/A — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 8-K — QUEST DIAGNOSTICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| form 4 | Form 4 — WENTWORTH TIMOTHY C | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 144 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 144 — QUEST DIAGNOSTICS INC | View Filing | |
| edgar index | 144 — QUEST DIAGNOSTICS INC | View Filing | |
| form 4 | Form 4 — Plewman Patrick | View Filing | |
| form 4 | Form 4 — PREVOZNIK MICHAEL E | View Filing | |
| form 4 | Form 4 — Doherty Catherine T. | View Filing | |
| edgar index | 4 — QUEST DIAGNOSTICS INC | View Filing |